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Abstract
The 6th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay was held under
the auspices of the Albert B. Sabin Vaccine Institute on March 10–13, 2004. The Colloquium
consisted of a select group of 34 scientists representing academia, biotechnology and
pharmaceutical industry. The main goal of this gathering was to promote in a peaceful and
comfortable environment exchanges between basic and clinical science. The secondary benefit was
to inspire novel bench to bedside ventures and at the same time provide feed back about promising
and/or disappointing clinical results that could help re-frame some scientific question or guide the
design of future trials. Several topics were covered that included tumor antigen discovery and
validation, platforms for vaccine development, tolerance, immune suppression and tumor escape
mechanisms, adoptive T cell therapy and dendritic cell-based therapies, clinical trials and
assessment of response. Here we report salient points raised by speakers or by the audience during
animated discussion that followed each individual presentation.
The Colloquium as a unique venue to promote 
cultural exchanges
Walker's Cay, is a minute tropical island in the northern-
most part of the Bahamas archipelago of a size barely suf-
ficient for a runway, a lodge and a harbor. Relaxation and
introspection are the only option. Visitors make the
majority of the population possibly giving Walker's Cay
the highest density of scientists per capita in the World on
the days of March 10–13, 2004. In that solitude, the
Robin Crusoe in each one of us was more than delighted
to educate impromptu Fridays on philosophical matters
such as signal transduction and growth regulation or
more practical ones such as clinical trial conduct and reg-
ulatory hurdles. Although apparently indulgent, this
atmosphere promoted comradery and intense exchange
of ideas based on the simple principle that scientists, like
most human beings, cannot refrain from talking. Formal
presentations served topics for discussion during subse-
quent free intervals when participants could cluster or dis-
perse at their leisure to deepen their discussions. The key
element of this successful recipe was, rather than the con-
finement, the selection of participants from distant disci-
plines so that most had never met each other before nor
known each other's work. When the time came to leave
Walker's Cay, most of us had gained new friends, a better
understanding of advances carried by our peers and, more
practically, new collaborations.
The Keynote lecture
Rolf Kiessling (Karolinska Institute, Stockholm, Sweden)
opened the Colloquium delivering the keynote lecture
about: "The Her-2/neu gene as a target for tumor vaccina-
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protein that is over-expressed by a proportion of tumors
such as breast, ovarian, gastric and colorectal carcinomas
with a frequency of approximately 20 to 30%. Its over-
expression is associated with malignant transformation of
epithelial cells and the frequency of over-expression varies
among types of cancer, but universally represents a marker
of poor prognosis. The critical role of HER-2 in epithelial
oncogenesis and its selective over-expression on malig-
nant tissues makes it an ideal target for immunotherapy.
Antibodies and T cells reactive to HER-2 are known to nat-
urally occur in patients with HER-2 positive tumors, con-
firming the immunogenicity of the molecule. Both
antibodies as well as T cells reactive to HER-2 have been
utilized for immunotherapy of HER-2 positive tumors.
The "humanized" monoclonal antibody Herceptin has
been tested in several clinical trials and found to be an
effective adjuvant therapy for HER-2 positive breast and
ovarian cancer patients. However, the frequency of
patients responding to Herceptin is limited and a majority
of patients initially responding to Herceptin develop
resistance within a year of treatment. The use of vaccina-
tion strategies that generate T cell responses with or with-
out accompanying antibody responses may serve to
mitigate the problem. Various strategies for generating T
cell-mediated responses against HER-2 are currently being
examined in animal models [1] or in clinical trials [2].
Clinical trials based on Her-2/neu vaccination are ongo-
ing at the Karolinska Institute and include a pDNA vacci-
nation with full length Her-1 combined with GM-CSF and
IL-2 in patients with advance breast cancer also on Her-
ceptin treatment and a multi-CTL epitope peptide vacci-
nation combined with GM-CSF and IL-2 in patients with
advanced ovarian cancer. Besides these clinical studies
strategies are being explored experimentally to avoid
epitope loss tumor variant using a multiple epitope
approach covering more than one oncogene, increasing
the binding affinity of known epitopes through HLA
anchor motif substitutions [3] and testing new adjuvants
that may include CpG motifs, construction of "smart"
viral vectors containing co-stimulatory molecules or
cytokines and the implementation of prime-boost strate-
gies using combinations of plasmid DNA, viral vectors or
protein products. A new strategy recently explored in the
use of polyoma VP1/VP2Her-2 viral like particles that
have shown effectiveness in animal models. Finally, strat-
egies should be implemented to avoid tumor escape. This
may be quite complex and involve the understanding of
tumor as well as host physiology. Several dogmas should
be re-assessed such as, for instance the relevance of MHC
expression down-regulation and its relationship with that
of pro-inflammatory cytokines such as IFN-γ in the tumor
micro-environment [4]. At the same time tumor induced
immune dysfunction should be taken into account and,
therefore, vaccination strategies should be combined with
treatment capable to reverse immune suppression.
Target antigen discovery and validation (Chair: 
Martin Kast)
Robert Vonderheide (Abramson Family Center Research
Institute, University of Pennsylvania, Philadelphia, PA)
talked about his work on: "Telomerase as a target for cancer
immunotherapy". High-level expression of the telomerase
reverse transcriptase (hTERT) are observable in >85% of
human cancers, in contrast to its restricted expression in
normal adult tissues. This observation points to hTERT as
a broadly applicable target for cancer immunotherapy.
Cytotoxic T lymphocytes (CTL) recognize peptides
derived from hTERT and kill hTERT+ tumor cells of mul-
tiple histologies in vitro. Moreover, because survival of
hTERT+ tumor cells requires functionally active telomer-
ase, hTERT may serve as a prototypic immune target for
which mutation or loss as a means of escape may be
incompatible with sustained tumor growth. Results of two
phase I studies of hTERT vaccination in cancer patients
were reported. In the first study (now closed), seven HLA-
A2 patients with advanced cancer (5 with prostate cancer,
2 with breast cancer) were vaccinated subcutaneously
with autologous monocyte-derived dendritic cells loaded
ex vivo with the hTERT HLA-A2 binding peptide I540. As
measured by peptide/MHC tetramer, ELISPOT, and cyto-
toxicity assays, hTERT specific T lymphocytes were
induced in 4 of 7 patients. Tetramer-guided high-speed
sorting and polyclonal expansion after vaccination
achieved highly enriched populations of hTERT-specific
cells that killed tumor cells in an MHC-restricted fashion.
Despite concerns of telomerase activity in rare normal
cells, no significant toxicity was observed, including in the
bone marrow. Partial tumor regression in one patient
with breast cancer was associated with the induction of
CD8+ tumor infiltrating lymphocytes. In a second study
(ongoing), patients with advanced breast cancer were vac-
cinated subcutaneously with I540 peptide emulsified in
adjuvant with GM-CSF. Among 9 patients treated thus far
at the first or second dose level, no serious adverse events
have been observed. Injection site reactions and tumor
pain following I540 peptide vaccination have occurred (in
contrast to our first trial). In one patient, tumor infiltrat-
ing lymphocytes associated with marked tumor necrosis
have been observed after vaccination. The lymphocytic
infiltrate included CD8+ and CD4+ T cells, macrophages,
dendritic cells, plasma cells, and B cells. Based on flow
cytometric tetramer analyses, 7%–10% of infiltrating
CD8+ T cells were specific for hTERT I540 peptide after
vaccination and were persistent for 7+ months. These
results demonstrate the immunological feasibility of tar-
geting telomerase as a tumor rejection antigen and pro-
vide rationale for telomerase vaccine trials in healthier
cancer patients [5].Page 2 of 11
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cussed: "Prostate cancer antigen discovery". In particular, he
presented a novel strategy for the identification of cancer-
specific proteins that could serve as molecular target of
vaccination. The significance of his model is based on the
ability to grow and characterize cancer cells from primary
tumors which notoriously are difficult to expand in vitro.
Dr. Bright presented an ingenious method for the immor-
talization of cancer cell lines through the transduction of
viral oncogenes such as the E6 and E7 sequences of
Human Papilloma Virus 16 based on a retroviral vector
[6]. In this fashion, several tumor and normal prostate
lines could be developed that could then be used to iden-
tify cancer-specific proteins using subtractive hybridiza-
tion and differential message display. Several new prostate
TAA, to include TPD52 (human and murine) and NY-CO-
25 were identified as either over expressed or uniquely
expressed in tumor cell lines. Tumor expression of candi-
date TAA was routinely confirmed by RT-PCR compared
to normal cell lines and commercially available normal
tissue panels, as well as with immune fluorescence and
western analysis when specific antibodies were available.
Immunogenicity and therapeutic potential; of novel pros-
tate TAA TPD52, was assessed in mice immunized with
DNA encoding the murine homologue. In separate exper-
iments, immunized animals failed to reject syngeneic 4T1
mammary tumor cells unless the tumor cells simultane-
ously expressed a second immunogenic tumor antigen,
suggesting in this case that mD52 DNA vaccination
induced some degree of anti-tumor immunity which led
to an immune response to the second tumor antigen (not
included in the vaccine). Relative immunogenicity of the
novel prostate TAA NY-CO-25 was tested using in vitro
sensitization technology and identified a single HLA-A2
restricted P9-modified (T to V) synthetic peptide capable
of inducing CTL with tumor reactivity. The systematic
development of methods for the successful establishment
of tumor and normal cell lines from primary and meta-
static cancer may help the identification of novel tumor
antigens particularly in those cases in which availability of
tumor cell lines is the limiting factor [7].
Maurizio Chiriva-Internati (Texas Tech University, Lub-
bock, TX) presented his experience in: "The complex valida-
tion of discovered cancer testis antigens". The salient point of
his presentation was that although cancer testis antigens
are believed to be specifically expressed only by tumors
and be germinal cells in the testis, comprehensive analysis
of tissue specimens from most organs identified a protein
cross-reacting to a cancer-testing antigen-specific anti-
body. Sperm protein 17 (Sp17) could be an ideal target
for the treatment of multiple myeloma and ovarian can-
cer, because it seems to have a very restricted distribution
in healthy tissues and in vivo clinical safety could be
deduced from the apparent lack of any pathological con-
dition in men who develop anti-Sp17 antibodies after
undergoing vasectomy. The expression of cancer associ-
ated antigens has mainly been studied at the level of gene
expression. However, this molecular approach does not
allow the quantification of cancer cells that are positive
for CT antigens. On the contrary, the availability of spe-
cific antibodies enables the recognition of the antigen
within examined tissues, highlighting not only the quan-
tity but also the type of cells expressing that antigen. Sp17
is strongly expressed in germinal cells and in the flagella
of spermatozoa. Because a common origin of cilia and
flagella in eukaryotes has been proposed, the expression
of Sp17 was investigated in human ciliated epithelia.
Indeed; Sp17 was detectable in ciliated epithelia of the
respiratory airways and both the male and female repro-
ductive systems questioning the usefulness of Sp17 in
immunotherapy protocols. Therefore, it was proposed
that validation of possible immunological targets for clin-
ical use should depend on
• Discriminating the cell types expressing the antigen on
the basis of the morphological visualization of all of the
parts making up the organ under investigation;
• Discriminating the antigen's sub-cellular localization
(nucleus, cytoplasm and plasma lemma);
• Mapping antigen expression in all of the organs making
up the living organism;
• Estimating the percentage of normal cells and their neo-
plastic counterparts expressing the antigen;
• Evaluating the dynamics of antigen expression at the
level of the cell cycle, the physiological status of the organism
and the process of aging.
Platforms of vaccine development (Chair: Matt 
Mescher)
Matt Mescher (University of Minnesota, Minneapolis,
MN) presented his view on: "Tumor immunotherapy with
large multivalent immunogen: murine models and clinical tri-
als". In particular, he presented a interesting in vivo mouse
model demonstrating that 3 signals are necessary for T call
activation. Effective activation of CD8 T cells by sub-cellu-
lar antigen or purified class I MHC protein/peptide com-
plexes requires that the Ag be presented on a surface of
cell-size dimensions. Administration of plasma mem-
brane tumor Ag immobilized on five-micron micro-
spheres (Large Multivalent Immunogen; LMI)
substantially increased generation of CTL responses to
syngeneic murine tumors, resulting in decreased tumor
growth and extended survival. A phase I trial of LMI treat-
ment of melanoma, using in vitro grown melanoma lines
as the source of plasma membrane antigen, showed LMIPage 3 of 11
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Increased CTL precursor frequency was found for eight of
fifteen patients [8]. A trial is currently underway examin-
ing treatment of melanoma and renal carcinoma using
autologous tumor as the source of membrane Ag. Ongo-
ing studies of murine tumor models, using adoptive trans-
fer of TCR transgenic cells to visualize CD8 T cell
responses in vivo, demonstrated that LMI prepared using
defined class I/peptide complexes are effective for treat-
ment of tumor-bearing mice and allow to define strategies
for improving the efficacy of LMI therapy, including co-
administration of cytokines and incorporation of co-stim-
ulatory ligands onto the microspheres. Insights gained
from studies visualizing vivo CTL responses in different
tumor models are suggesting that effective strategies for
immunotherapy will depend upon the status of the
patients tumor specific CD8 T cells at the time of treat-
ment, with different approaches being indicated depend-
ing upon whether the cells are naïve, Ag-experienced
effector cells, or cells that have interacted with Ag and
become tolerant. His work provides fundamental infor-
mation for the interpretation of the clinical finding that in
most cases vaccination-induced T cells do not seem to be
capable to eradicate cancer possibly because they do not
achieve a sufficient status of activation at the tumor site
[9].
Tibor Keler (Medarex, Inc., Bloomsbury, NJ) talked about
the: "Use of antibodies to target antigens for efficient cross-
priming of anti-tumor T cell responses". The proper uptake,
processing and presentation of TAA by antigen presenting
cells (APC) are critical for induction of potent CTL and
helper T cell responses. In particular, eliciting CTL
responses to exogenous protein antigens has been chal-
lenging. Human antibodies were developed to the man-
nose receptor and to the Type I Fc receptor (CD64) as a
means to deliver antigens for enhanced uptake, processing
and presentation of antigens by dendritic cells. Targeting
antigens to these endocytic receptors on DC results in effi-
cient presentation of the TAA in context of MHC class I
and class II molecules. In particular, co-cultures of autol-
ogous DC and T cells from healthy volunteers and cancer
patients can elicit CTLs that recognize and lyse tumor cells
expressing the TAA and sharing at least one HLA mole-
cule. These recombinant vaccines offer a novel approach
for eliciting cellular and humoral responses to defined
protein antigens [10].
W Martin Kast (University of Southern California, Los
Angeles, CA) presented data supporting the: "Anti-tumor
efficacy of Venezuelan equine encephalitis virus replicon
particles encoding mutated HPV16 E6 and E7 genes". An
effective vaccine for treating human papillomavirus
(HPV)-associated malignancies such as cervical cancer
should elicit strong T cell-mediated immunity (CMI)
against the E6 and/or E7 proteins necessary for the malig-
nant state. A vaccine was developed based on Venezuelan
equine encephalitis (VEE) virus replicon particle (VRP)
encoding the HPV16 E6 and E7 genes. VLP immunogenic-
ity and anti-tumor efficacy was tested. The E6 and E7
genes were fused to create one open reading frame and
mutated at four or at five amino acid positions to inacti-
vate their oncogenic potential. VRP encoding mutant or
wild type E6 and E7 proteins elicited comparable cyto-
toxic T lymphocyte (CTL) responses to an immunodomi-
nant E7(49–57) epitope and generated comparable anti-
tumor responses in several HPV16 E6(+)E7(+) tumor
challenge models: protection from either C3 or TC-1
tumor challenge was observed in 100% of VRP-vaccinated
mice. Eradication of C3 tumors was observed in approxi-
mately 90% of mice following therapeutic VRP vaccina-
tion. Eradication of HLF16 tumors lacking the E7 (49–57)
epitope was observed in 90% of human leukocyte antigen
(HLA)-A*0201 transgenic mice following vaccination.
Finally, the predicted inactivation of E6 and E7 oncogenic
potential was confirmed by demonstrating normal levels
of both p53 and retinoblastoma proteins in human mam-
mary epithelial cells (MEC) infected with VRP expressing
mutant E6 and E7 genes. These promising results support
the continued development of mutant E6 and E7 VRP as
safe and effective candidates for clinical evaluation against
HPV-associated disease [11].
Alain Luxembourg (Ichor Medical Systems, San Diego,
CA) described a novel method for the: "Potentiation of
DNA vaccines and cancer immunotherapy by electroporation".
DNA vaccines are a promising method for vaccination
against cancer antigens. They are appropriate to elicit T
cell responses, which offer new opportunities for achiev-
ing anti-tumor responses. They can comprise multiple
antigens, thereby minimizing risk of tumor escape by
mutation. The procedure has the potential to enable long-
term expression of the antigen, which could help sustain
immunological memory. In contrast to cell-based vac-
cines, DNA vaccination is not patient specific, which facil-
itates product development, standardization,
manufacturing and distribution. However, the translation
of these promising findings into clinical products has
proven difficult. In particular non viral delivery systems
seem to induce insufficient levels of gene expression espe-
cially in larger animals and humans. Electroporation (EP),
is a potent non-viral delivery technique utilizing the in
vivo application of electrical fields to enhance intracellular
uptake of nucleic acids. Based on the dramatic enhance-
ment of DNA delivery provided by EP, this technique may
provide a means to overcome some of the traditional hur-
dles associated with the use of plasmid DNA vaccines. In
order to be considered a viable platform for DNA-based
immunization in the clinical setting, a method for effec-
tive, reproducible EP-mediated DNA vaccine deliveryPage 4 of 11
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venient, well tolerated, and cost effective. Ichor's proprie-
tary TriGrid™ intramuscular delivery technology addresses
these issues by providing an integrated, automated appli-
cation system. The system consists of three components: a
Pulse Stimulator, an Integrated Applicator, and a single
use Application Cartridge. Of principal importance,
Ichor's technology provides a user independent means of
application, assuring effective and reliable propagation of
the EP-inducing electrical fields at the site of agent admin-
istration.
Sally Mossman (Corixa Corporation, Seattle, WA)
reported on Corixa experience in: "WT-1 cancer vaccine
development: protein-based approaches to inducing comprehen-
sive immunity". Gene based vaccines, such as viral vectors,
have proved highly efficient at generation of CD8+ T cell
responses, particularly in mouse models, but can be defi-
cient at inducing a potent CD4+ helper T cell response. In
addition, viral vectors can be used effectively only a lim-
ited number of times due to induction of vector-specific
neutralizing responses in the host. For these reasons effec-
tive antigen delivery may require the administration of
recombinant protein antigen into the Class I pathway,
while simultaneously inducing strong CD4+ T cell
responses and high titers of serum antibody. Protein-
based approaches afford the opportunity for delivering
multiple boosting immunizations. WT-1 is a tumor-asso-
ciated antigen first identified in Wilm's Tumor. It repre-
sents a promising target for development of a therapeutic
leukemia vaccine since its expression is highly tumor-spe-
cific. A truncated WT-1 construct in which the highly con-
served zinc finger region was deleted resulted in
dramatically improved immunogenicity in vivo. Two dif-
ferent protein-based vaccine approaches were able to
induce a WT-1 specific HLA-A2 – restricted CD8+ T cell
response, high levels of antigen specific IFN-γ secretion
from CD4+ T cells and significant titers of IgG1 and IgG2a
WT-1-specific antibodies in HLA-A2 transgenic mouse
models. The first approach utilized a potent adjuvant for-
mulation consisting of the combination of TLR4 and
TLR9 agonists in a squalene oil emulsion. The second
approach employed WT-1 protein co-encapsulated in a
poly(lactide co-glycolide) microsphere with MPL® adju-
vant. This latter vaccine formulation in particular is likely
to be extremely safe and non-reactogenic in the clinic, and
should provide an efficient method for immunizing
patients with WT-1-positive hematologic malignancies.
Gerry Rowse (Stressgen Biotechnologies, Victoria, BC,
Canada) summarized the use of: "Hsp-fusion proteins: a
platform technology for the treatment of chronic viral diseases
and cancer". There are likely many different reasons for the
limited success of immunotherapeutic treatments, but
one important problem has been the difficulty of generat-
ing strong, sustained immune responses of the correct
immune polarity to key antigenic targets on diseased cells.
Evidence suggests that to be effective, an immune
response against viral disease and cancer must involve a
strong cell-mediated response. A platform technology was
developed for the immunotherapeutic treatment of
chronic viral diseases and cancer based on the concept of
fusing antigenic molecules to highly immunogenic bacte-
rial heat shock proteins (CoVal™ fusions). The fusion of
antigens to heat shock proteins (Hsp's) results in the
development of Th1-biased immune responses and the
generation of cytolytic T lymphocytes even when Hsp-
fusion proteins administered without adjuvants. HspBCor
is a CoVal™ fusion protein engineered from HBV core
antigen (HBc) and Hsp65 from Mycobacterium bovis BCG.
Re-stimulated splenocytes from C57BL/6 mice immu-
nized with HspBCor in saline displayed a high level of H-
2Kb-restricted lytic activity. HspBCor was similarly effec-
tive at eliciting HLA-A2-restricted CTL in HLA-A2Kb trans-
genic mice. HspBCor-primed CTL lysed both peptide-
pulsed and HBc-transfected target cells, which express
HBc endogenously. IFN-γ was also released by HspBCor-
primed CTL. Induction of CTL was further evaluated in
HBV transgenic mice, which are commonly employed as
a model of chronic HBV infection. A single injection of
HspBCor was observed to elicit CTL in a proportion of
transgenic mice, despite the immunological tolerance to
HBV antigens in these animals. These data support the
hypothesis that the CoVal™ fusion protein, HspBCor, will
be an effective agent in the immunotherapy of chronic
HBV infection and its resultant liver cancer
John Vasilakos (3M Pharmaceuticals, St Paul, MN)
reported that: "Synthetic TLR agonists reveal functional dif-
ferences between human TLR7 and TLR8". In particular,
John discussed a recent study in which TLR agonists were
shown to protect mice against B16 melanoma when used
in concert with CD40L. Stimulation of TLR7 and TLR8
appears to modulate the function of innate immunity by
promoting the production of TNF-α and interleukin-1
and MIP-1α (TLR4 and TLR8) or IFN-α or IFN regulated
chemokines such as IP-10 and I-TAC (TLR7). Th eTLR7
agonists directly activates plasmacytoid DC and B-cells
and, to a lesser extent monocytes. Conversely, TLR8 ago-
nists directly active myeloid DC, monocytes and mono-
cyte-derived DC. In vivo, small molecule TLR7 agonists
enhance Th1-like immunity and activate class I-restricted
CD8 T-cells in mice. CD8 T-cell activation directly corre-
lates with anti-tumor immunity. It also appeared that
most of the effect of TLR 4/8 agonists is mediated through
activation of the NF-kB pathway while it remains unclear
which is the predominant pathway utilized by TLR-7 ago-
nists. One of the difficulties in interpreting the data
regarding the mechanism of action of TLR agonists in vivo
in animal models is their stringent species specificity andPage 5 of 11
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anism of action directly in humans [12].
Tolerance, immune suppression and tumor 
escape mechanisms (Chair: Hyam Levitsky)
Tyler Curiel (Tulane University, New Orleans, LA) pre-
sented: "Tumor-mediated immune escape and immune sup-
pression". Recent evidence suggests that tumors actively
defeat specific immunity through a variety of mecha-
nisms, most of which remain poorly understood. In
human ovarian cancer, it was demonstrated that tumor-
conditioned dendritic cells (DC) are dysfunctional in
many regards, including inducing suppressive IL-10-pro-
ducing T cells. Tumor plasmacytoid DC are conditioned
through tumor stromal-derived factor-1 to induce IL-10-
secreting T cells. Tumor myeloid DC are conditioned
through tumor VEGF and microenvironmental macro-
phage IL-10 to express B7-H1, which induces T cell IL-10
and inhibits tumor associated antigen (TAA)-specific
immunity. The T cells induced by these tumor-condi-
tioned DC displayed many properties of regulatory T cells.
CD4+CD25+ Tregs are elevated in many humans with can-
cer, although their functional significance is unclear.
Human tumor CD4+CD25+ Tregs block TAA-specific
immunity in vivo, and are associated with reduced cancer-
specific survival in humans. Endogenous tumor-mediated
suppressive functions may explain the relatively poor clin-
ical results in most cancer vaccine trials. Ontak is a fusion
protein consisting of the CD25-binding domain of IL-2
fused to the active domain of diphtheria toxin. Ontak kills
CD4+CD25+ Tregs and thus improves immunity in cancer
patients. Three patients (one each with advanced-stage
cancer of the ovary, breast or lung) received a single intra-
venous infusion of 9 µg/kg Ontak. Patients had been
heavily treated, but had received no cytotoxic drugs, radi-
ation therapy or immune modulating agents for at least
30 days prior to study entry and had no autoimmune dis-
ease or active immunologic processes aside from their
cancer. Prior to infusion, the mean prevalence of
CD4+CD25+ cells in blood CD4+ T cells blood was 9.0 %,
which fell to a mean of 5.2 % three days after infusion (P
= 0.0007). Prior to infusion of Ontak, there were a mean
of 27.6 CD4+CD25+ cells/mm3 in blood which fell to 11.9
CD4+CD25+ cells/mm3 three days after Ontak. The total
number of CD4+CD25+ cells decreased approximately
50% in each patient. The prevalence of interferon-γ+CD8+
T cells increased a mean of 40% accompanied by a corre-
sponding increase in the absolute number of interferon-
γ+CD8+ T cells after Ontak. The prevalence of the prolifer-
ation marker Ki-67+ T cells in blood increased significantly
from 0.93% before Ontak to 4.5% of all T cells three days
after treatment. The treatment was well tolerated. This
strategy, or others designed to defeat tumor-mediated
immune suppression, may be combined with active
immunization for optimal cancer vaccine efficacy [13].
Soldano Ferrone (Roswell Park Cancer Institute, Buffalo,
NY) presented his novel strategy for: "Monitoring HLA class
I antigen-tumor antigen peptide complexes on melanoma cells".
To date, a number of studies have clearly demonstrated
that HLA class I antigens as well as components of the
antigen processing machinery (APM) are frequently
down-regulated and/or lost in malignant lesions. The
information remains scant because of the need of devel-
oping reagents that can be used in paraffin sections repre-
senting most available clinical material. Recent work from
his laboratory lead to the production of monoclonal anti-
bodies utilizing a semi-synthetic phage display antibody
library able to measure the expression of specific HLA
class I-tumor antigen peptide complexes (in this particular
case a peptide epitope from the melanoma associated
antigen MART-1). Preliminary data suggested that there is
poor correlation between HLA class I expression on
number of HLA-MART-1 complexes suggesting that the
simple analysis of HLA complexes may be misleading
because it does not take into account the efficiency and
individual tumor antigen processing and presentation by
cancer cells.
Hyam Levitsky (Sidney Kimmel Comprehensive Cancer
Center, John Hopkins School of Medicine, Baltimore,
MD) talked about the: "Visualization of tumor antigen spe-
cific CD4+ T cell suppression". CD4+ tumor-specific T cells
have impaired function and cannot be primed in vivo.
Using the adoptive transfer of CD4+ T cells from TCR
transgenic mice labeled with CSFE it was possible to dem-
onstrate the kinetics of in vivo proliferation of T cells in
naïve non-tumor bearing animals and tumor bearing
mice. Adoptive transfer of transgenic CD4+ T cells recog-
nizing an MHC class II restricted epitope of influenza
hemagglutinin (HA) into mice harboring a systemic B cell
lymphoma expressing HA (A20HA) demonstrated evi-
dence of antigen recognition. Clonotype+ T cells under-
went a modest expansion, and displayed a phenotype
consistent with antigen-experienced T cells. Analysis of
cell division by CFSE dilution revealed that only a minor-
ity of the HA-specific T cells enter the cell cycle, in spite of
a progressively expanding systemic tumor burden. Sorting
HA-specific CD4+ T cells from A20HA bearing mice into
CFSEhi (undivided) and CFSElo (divided) populations
identified that while the former respond to HA peptide
equivalently to naïve HA-specific T cells in vitro (prolifer-
ation and IL-2 production), the divided cells displayed
markedly impaired responses. Furthermore, while immu-
nization of A20HA bearing mice with HA-expressing virus
increased the number and fraction HA-specific T cells that
have divided, this "primed population" also had a mark-
edly impaired proliferative response to peptide in vitro,
diminished IL-2 production, and failure to make inter-
feron-γ as compared to CFSElo HA-specific T cells from
virus primed, non-tumor bearing mice. Limited gene pro-Page 6 of 11
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mice demonstrated less mRNA for IL-2, CD40L, t-bet, and
IFN-γ following TCR cross-linking than similarly treated
naïve or virus primed T cells from non-tumor bearing
mice. In contrast, message for IL-10, GITR, foxp-3, and
LAG-3 were markedly increased in tumor-specific, anti-
gen-experienced T cells. In vitro mixing of CFSEloHA-spe-
cific T cells purified from A20HA bearing mice with naïve
HA-specific "responder" T cells resulted in profound sup-
pression of proliferation, and IL-2 production. Remarka-
bly, divided HA-specific T cells from A20HA bearing mice
also suppressed IFN-γ production of CD4+ effector cells
purified from virus primed, non-tumor bearing mice.
Trans-well experiments demonstrated the requirement for
cell:cell contact for suppression. Suppression was antigen-
specific, as mixing CFSEloHA-specific T cells from A20HA
bearing mice with naïve OVA-specific CD4+ T cells had no
impact on proliferation or IL-2 production when pulsed
with both HA and OVA peptides in vitro. Finally, sorted
CFSElo HA-specific CD4+ T cells (thy1.1+/+) obtained from
A20HA bearing mice were mixed with naïve HA-specific
responder T cells (thy1.1+/1.2+) and injected into non-
tumor bearing recipients, which were then primed with
HA-expressing virus. Whereas both populations divided
in response to infection, the presence of the putative sup-
pressor population significantly diminished the accumu-
lation of the responder T cells and blocked their
differentiation into INF-γ producing Th1 cells.
Stephen Schoenberger (La Jolla Institute, San Diego, CA)
presented: "A TRAIL of death for helpless CTLs". The goals
of cancer immunotherapy could be significantly advanced
through a detailed and mechanistic understanding of the
immunobiology of cytotoxic CD8+ T lymphocytes (CTL).
Whereas the initial clonal expansion of CTL can proceed
in the absence of CD4+ T lymphocytes, their ability to
undergo secondary expansion upon re-exposure to anti-
gen is wholly dependent on the presence of CD4 T help
during priming. Thus, CTL primed in the absence of T
help ("helpless" CTL) can function as cytotoxic effector
functions in a recall response, but do not subsequently
undergo secondary expansion. The helpless CTL follow-
ing re-stimulation undergo an abortive expansion leading
to death via a caspase-dependent apoptosis. The relevance
of the known pro-apoptotic pathways to the death of
helpless CTL was then investigated using a genetic
approach. These experiments ruled out a role for either the
so-called "passive" (mitochondrial) death pathway the
Fas-Fas-L or TNF-R death receptor pathways in the disap-
pearance of helpless CTL following re-stimulation. In con-
trast, the combined molecular and genetic data indicate
that the TRAIL/TNF-R2 (DR5) pathway is responsible for
the activation-induced cell death (AICD) observed when
helpless CTL encounter antigen for the second time. The
results provide new insights into the role of TRAIL in
immune regulation and reveal new targets for therapeutic
intervention [14].
Hans Schreiber (University of Chicago, Chicago, IL) pre-
sented: "Bystander elimination of antigen loss variants in
established tumors". T cells activated in mice bearing
tumors expressing high levels of antigen can kill synchro-
nous tumors with low antigen expression. These tumors
would not be killed in the absence of concomitant immu-
nity. In humans, it is likely that most tumors are express-
ing relatively low level of antigens and this is why they can
grow. Possible, the enhancement of antigen expression or
presentation in some tumors through local stimulation be
cytokines or other factors could induce anti-tumor immu-
nity and subsequent epitope spreading activating T cells
against several tumor antigens present in the tumor. These
may in turn be capable of destroying distant tumors. This
hypothesis has not been tested in humans as yet though
several groups have advocated increasing the immuno-
genic potential of individual lesions in vivo through local
immune stimulation as a possible tool to induce immune
responses toward synchronous autologous metastases
[15].
Eduardo Sotomayor (Moffitt Cancer Center, Tampa, FL)
presented: "Molecular strategies to overcome tumor-induced
immune tolerance and enhance the efficacy of cancer vaccines".
His work suggests that most tumors are infiltrated with
tolerogenic antigen presenting cells with high expression
of STAT-3, cKIT and hsitone de-acetylase. It could be pos-
sible to revert this process by administering inhibitors of
these molecules in combination with vaccination. Several
putative molecules were discussed such as LAQ-842, an
inhibitor of histone de-acetylase [16].
Hua Yu (Moffitt Cancer Center, Tampa, FL) presented her
work on the: "Role of Stat3 in oncogenesis, tumor immune
evasion and immunotherapy". For a tumor to reach clinical
stage, it must be able to resist apoptosis, sustain prolifera-
tion, attract nutrients through angiogenesis and evade
immune detection. As a point of convergence for many
oncoproteins, signal transducer and activator of transcrip-
tion 3 (Stat3) protein participates in regulation of all of
these processes and is activated in a very large number of
cancers. Stat3 promotes tumor cell growth by regulating
genes critical for survival and proliferation. A master regu-
lator of vascular endothelial growth factor, Stat3 is also
critical for tumor angiogenesis. Blocking Stat3 leads to
tumor cell apoptosis, tumor vessel impairment and tumor
regression. While the mechanism linking oncogenesis and
immune evasion has been elusive, our recent data indicate
that oncogenic signaling pathways use Stat3 to shield can-
cer from the immune system. Stat3 activity in tumor cells
inhibits the production of pro-inflammatory cytokines
and chemokines while inducing the release of factors thatPage 7 of 11
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of Stat3 in DCs. Blocking Stat3 in tumor cells allows pro-
duction of inflammatory mediators, leading to activation
of both innate and adaptive immune responses. Moreo-
ver, inhibition of Stat3 in immune cells unleashes potent
anti-tumor immune responses. Specifically, in vivo dele-
tion of the Stat3 alleles in bone marrow cells enables DCs
to escape tumor-induced maturation inhibition, leading
to T cell activation. Additionally, the ability of Stat3-/- NK
cells and neutrophils from tumor-bearing mice to kill
tumor cells is considerably enhanced compared to their
Stat3+/+ counterparts. Growth of B16 and MB49 tumors in
mice with Stat3-null bone marrow cells is significantly
inhibited. In summary the blockage of Stat3 – in either
tumor or immune cells – stimulates anti-tumor immune
responses. With the emergence of Stat3-specific pharma-
cologic inhibitors, molecular targeting to modulate host
Stat3 activity is expected to evoke anti-tumor immunity
and strengthen the efficacies of a variety of immunothera-
peutic approaches [17].
Adoptive T cell therapy and dendritic cell (DC) 
based therapies (Chair: Michael Nishimura)
Bernard Fox (Earle A. Chiles Research Institute, Portland,
OR) proposed to: "Exploit lymphopenia to reboot immune
response to cancer". A primary reason for the failure of can-
cer vaccine strategies is because the magnitude of the anti-
tumor immune response is insufficient to mediate tumor
regression. Recently, we described a novel strategy to aug-
ment priming of tumor-specific T cells by vaccinating lym-
phopenic mice that had been reconstituted with 2 × 107
spleen cells. Tumor vaccine-draining lymph nodes
(TVDLN) of reconstituted-lymphopenic mice (RLM) vac-
cinated with D5-G6, a GM-CSF-secreting line of the
poorly immunogenic B16BL6-D5 (D5) melanoma, con-
tained an increased number of activated T cells (OX-40,
LY6C, CD62Llow) [18]. Following in vitro activation and
expansion these TVDLN exhibited an increased frequency
of tumor-specific CD4 and CD8+ T cells that correlated
with significantly (p < 0.05) increased therapeutic efficacy
in adoptive transfer studies. This strategy was also effective
in an active-specific vaccine strategy, significantly aug-
menting the generation of a protective immune response
against the weakly immunogenic B16-F10 melanoma
[19]. While initial studies were performed in congenitally
lymphopenic RAG-1 or irradiated mice, current studies
examined whether lymphopenia induced by chemother-
apy would be effective in our RLM strategy. Lymphopenia
induced by cyclophosphamide (CY) was tested for its
effect on the number of activated T cells in TVDLN of
RLM. One or two days following drug administration
mice were reconstituted with spleen cells and vaccinated
with D5-G6. TVDLN were harvested 8 days later and T
cells analyzed for expression of activation markers. The
addition of CY substantially increased the percentage of
CD62Llow / CD44+ T cells with the greatest increase
observed at the highest dose of CY. A similar correlation
was observed between CY dose and frequency of tumor-
specific T cells with therapeutic efficacy (Ma, J., et al., sub-
mitted). While the RLM strategy clearly augments the ther-
apeutic effectiveness of vaccine strategies, these studies
reconstituted lymphopenic mice with spleen cells (SC)
from naive mice. Using SC from systemic-tumor-bearing
mice (TBM) in the RLM strategy resulted in reduced fre-
quencies of tumor-specific IFN-γ secreting effector T cells
that could not mediate regression of pulmonary metas-
tases in adoptive transfer studies. The question was then
addressed of whether depletion of CD25+ cells from SC of
TBM used in the RLM strategy would improve the anti-
tumor effect. Effector T cells generated from mice reconsti-
tuted with CD25-depleted TBM SC had their frequency of
tumor-specific IFN-γ secreting T cells and therapeutic effi-
cacy restored (Poehlein, C.H., et al., submitted). Clinical
trials of the RLM strategy are presently under preparation,
these findings may provide information that can be used
to monitor and/or improve the translation of this strategy
to the clinic. Clinical trials of this strategy are planned in
melanoma, prostate cancer (W.J. Urba and B. Curti, Earle
A. Chiles Research Institute), non small cell lung cancer
(D. Ruettinger, Klinikum Grosshadern, LMU, Munich,
Germany) and ovarian cancer (J. Ma, Xi'an Jiaotong Uni-
versity, Xi'an, China) patients.
Michael Nishimura (University of Chicago, Chicago, IL)
presented is work on: "T cell receptor gene modified T cells
for the immunotherapy of cancer". His word demonstrated
that TCR with high affinity for their ligand become CD4
or CD8. For instance, a CD4 clone recognizing a
melanoma antigen could interaction in an HLA class I
restricted fashion with tumor cells. Selection and cloning
of T cells characterized by high affinity and independence
from co-receptor support may be a useful tool to identify
the most relevant anti-cancer agents. Genetic transfer of
such constructs into T cell for adoptive transfer would
have several advantages. Not only it would provide a high
avidity T cell receptor for any patient but knowledge of the
specific sequence would allow tracking of the localization
of the adoptively transferred T cells using clonotype spe-
cific probes for quantitative real-time PCR or other detec-
tion methods. Finally, ability of producing T cells
expressing two T cell receptors could be considered so that
T cells bi-specific for a viral and, at the same time, a tumor
antigen could be adoptively transferred allowing one to
be activated by the other specificity using various vaccina-
tion models [20].
Michel Sadelain (Memorial Sloan-Kettering Cancer
Center, New York, NY) presented: "Targeting tumors with
genetically enhanced lymphocytes". Two scFv/ζ chain-based
chimeric antigen receptors specific for CD19 (B cell line-Page 8 of 11
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marker) could be introduced in T lymphocytes to eradi-
cate tumors in various mouse models. Although redirec-
tion of the T cell response through TCR transfer other
requirements appeared necessary including co-stimula-
tion with CD880 and IL-15 which increased the persist-
ence of adoptively transferred cells. The study showed that
if T cells are given in sufficient number and properly acti-
vated, further co-stimulation in vivo in not necessary and
they can survive for a period long enough to completely
eradicate tumor deposits [21].
David Urdal (Dendreon Corporation, Seattle, WA)
reported on: "Immunotherapy of cancer: progress in the devel-
opment of Provenge® in prostatic cancer". Provenge® is a ther-
apeutic vaccine composed of autologous antigen
presenting cells cultured ex vivo with a recombinant
fusion antigen consisting of Prostatic Acid Phosphatase
(PAP) linked to granulocyte macrophage colony stimulat-
ing factor. The drug is in the final stage of clinical evalua-
tion in men with androgen-independent prostate cancer.
Results from a completed phase 3, double-blind placebo
controlled, trial suggest that in men with Gleason ≤ 7
tumors, Provenge delays disease progression, delays the
onset of disease related pain and results in a survival
advantage when compared to patients who had been ran-
domized to placebo [22].
Clinical trials and immune assessment or 
response (chair Francesco M Marincola)
Neil Berinstein (Aventis Pasteur, Toronto, ON, Canada)
presented the: "Induction of CD8+ T cell responses to
melanoma with tumor-antigen expressing canary pox vectors".
The canary pox vector Alvac was used to induce specific
CD8+ T cell responses to melanoma cells bearing the
gp100 melanoma differentiation antigen. A full-length
cDNA for gp100 was engineered into the Alvac vector with
modifications to the HLA A*02010-associated CTL
epitopes at positions 209 and 280 to increase binding
affinity to the HLA molecule. Thirty-six patients were
treated in a multi-centre phase I trial which evaluated
prime boost approaches with Alvac and the gp100:209-
2M and gp100:280-9V peptides, different routes of
administration of the vaccines and whether non-specific T
helper adjuvant tetanus toxoid could enhance the
responses. The vaccine was found to be safe. Elispot and
tetramer assays for T cell responses after in vitro cell culture
demonstrated: 1) heterologous prime boost immuniza-
tions with Alvac 2 gp100M and peptides generated meas-
urable increases in gp100 reactive T cells 2) the viral
component of the vaccine was required for T cell induc-
tion as peptides alone were completely ineffective 3)
intra-nodal administration appeared more effective than
subcutaneous vaccination 4) patients receiving tetanus
toxoid had lower T cell responses than the non-tetanus
toxoid groups 5) most vaccine-induced responses were
not long lived as gp100 reactivity returned to baseline by
the end of the study. 6) Classical clinical responses were
not seen with the vaccine alone but were seen in 2 of 7
patients (only three of whom had measurable disease)
treated with high dose Interferon-α post vaccination.
These responses were associated with recall of Gp100 spe-
cific CD8 T cells with enhanced functional (lytic) activity
[23].
Ivan Borrello (John Hopkins University, Baltimore, MD)
showed data demonstrating that: "Activated marrow infil-
trating lymphocytes impart a strong anti-tumor effect on
plasma cells and their clonogenic precursors: a novel approach
to adoptive immunotherapy". In multiple myeloma, marrow
infiltrating lymphocytes (MILs) can be easily obtained
and expanded with significant tumor specificity utilizing
an artificial antigen presenting cell consisting of anti-
CD3/antiCD-28 antibodies coupled to a magnetic bead.
This in vitro activation of MILs results in an 8–10 fold
increase in tumor specificity as compared to unactivated
MILs and contrasts with nomeasurable tumor specificity
in either activated or unactivated circulating lymphocytes.
The anti-tumor activity of activated MILs targeted the ter-
minally differentiated CD138+ plasma cells as well as the
myeloma precursor and inhibitied growth of myeloma
precursors in a clonogenic assay. Activation within the
marrow microenvironment is critical to enhancing tumor
specificity as isolation of MILs from the marrow and sub-
sequent activation significantly reduced their tumor spe-
cificity thereby underscoring the critical requirement of
antigen exposure during both the activation and expan-
sion phases. The ability to augment the therapeutic anti-
tumor efficacy of adoptive immunotherapy will hopefully
translate into clinically measurable advances in the treat-
ment of multiple myeloma and as well as other hemato-
logic malignancies (Anti-myeloma activity of activated
marrow infiltrating lymphocytes: a novel approach to
adoptive immunotherapy. Noonan, K et al submitted).
Lother Finke (EMD Pharmaceuticals inc., Durham, NC)
reported on: "An international, randomized phase III clinical
trials of STn-KLH (Theraptope®) therapeutic cancer vaccine in
metastatic breast cancer patients". Theratope is an investiga-
tional therapeutic cancer vaccine consisting of a synthetic
form of the tumor associated antigen Sialyl Tn (STn) con-
jugated to the carrier protein keyhole limpet hemocyanin
(KLH). In a phase III clinical trial, patients with metastatic
breast cancer patients (MBC pts) who had no evidence of
disease or non-progressive disease following any first-line
chemotherapy were randomized 1:1 to receive adjuvant
plus Theratope or control [adjuvant plus KLH]. All pts
received a single IV infusion of cyclophosphamide before
vaccine. Primary endpoints were time to disease progres-
sion (TTP) and overall survival (OS). Pts were stratified byPage 9 of 11
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The randomization included 1,028 patients: 32% received
concurrent HT. Median TTP and OS for Theratope (T) and
control (C) pts were slightly but not significantly better in
the population of patients receiving HT. Theratope was
generally well tolerated. Injection site ulcerations
occurred with similar frequency in the Theratope and con-
trol groups (17.5% vs. 17.6%); 8% of pts discontinued
due to adverse events. A phase II study in ER positive MBC
pts receiving HT and Theratope is currently underway.
Kristen Hege (Cell Genesys Inc., South San Francisco,
CA) presented: "GVAX cancer vaccines – clinical develop-
ment". GVAX cancer vaccines are composed of whole
tumor cells genetically modified to secrete GM-CSF which
has the advantage of a prolonged release over injection of
the cytokine at the time of vaccination. Sources of tumor
cells for vaccine manufacturing include both autologous
cells derived from individual patients as well as allogeneic
tumor cell lines. Clinical development of the various
GVAX vaccine platforms in prostate, lung, and hemato-
logic cancers will be reviewed. Autologous vaccines have
been performed in the context of renal cell cancer,
melanoma, prostate and non-small-cell lung cancer. Allo-
geneic vaccines in the context of prostate and pancreatic
cancer. Bystander GVAX refers to the utilization of autolo-
gous tumor cells mixed with allogeneic cell lines modified
to secrete GVAX and have been utilized in the context of
multiple myeloma and AML. In prostate cancer allogeneic
vaccines have been shown to induce increases in GM-CSF
levels and induce tumor reacting antibodies by Western
Blot. In addition, decreases in PSA levels have been noted
with an association with a trend to improved survival.
Autologous vaccines in lung cancer have been associated
with complete responses particularly in the case of alveo-
lar carcinoma and a significant increase in survival [24,25]
Kim Lyerly (Duke University, Durham, NC) discussed:
"Antigen specific cellular immune responses following DC-base
vaccination". DCwere matured with a combination of LPS,
CD40L and IFN-γ and various immunizations were per-
formed particularly using a pox-vector encoding CEA or
mRNA. Immune monitoring demonstrated a close corre-
lation among assays performed which included ELISPOT,
intra-cellular cytokine staining and tetrameric HLA/com-
plexes analysis.
Francesco M Marincola (Clinical Center, National Insti-
tutes of Health, Bethesda, MD) described strategies for
the: "Monitoring of anti-cancer immune responses". In partic-
ular, the NIH experience using tumor antigens recognized
by T cells for active immunization trials was discussed.
These vaccines mostly left the clinicians and researchers
perplexed by the paradoxical observation of the immuni-
zation-induced T cells can recognize tumor cells in stand-
ard assays but most often cannot induce tumor regression.
Indeed, successful immunization is one of several steps
required for tumor clearance but more work needs to be
done to understand how T cells can localize and be effec-
tive at the receiving end within a tumor microenviron-
ment in most cases not conducive to the execution of their
effector function. In fact, metastatic melanoma stands out
among human cancers because of its immune responsive-
ness. Yet, the reason(s) remain(s) unclear. A promising
strategy for the understanding of melanoma immune
responsiveness could consist of the study of tumor/host
interactions ex vivo through genetic profiling of serial fine
needle aspirate biopsies that allow direct correlation
between experimental results and clinical outcome. By
prospectively studying the transcriptional profile of
melanoma metastases during immunotherapy it was pos-
sible to observe that immune responsiveness is pre-deter-
mined by an immune reactive micro-environment.
Interestingly, the addition of systemic interleukin-2 ther-
apy to active specific immunization seems to increase the
frequency of immune rejections of cancer. Functional pro-
filing of the effect of interleukin-2 in tumors suggested
that this cytokine induces or enhances the effector func-
tion of immunization-induced T cells by causing an acute
inflammatory process at the tumor site that can in turn
recruit and activate T cells[26]. Future clinical studies
should incorporate tools that allow global monitoring of
immune responses with high-throughput systems that
could take into account the genetic make up of patients,
the transcriptional profile of tumor and circulating lym-
phocytes and the expression of relevant protein products
[27-29]
Conclusions
It may appear difficult to make final conclusions given the
diversity of the topics covered. However, one remark can-
not be passed up; balanced meetings such as the Walker's
Cay symposium address the need for intense interaction
among basic scientist, clinical researchers and product
development favoring in its essence the recognized need
for translational efforts for health care improvement
[30,31] Several issues could be addressed in the bench to
bedside and bedside to bench direction among scientists
beyond the specifics of each individual's research so that,
when the plane arrived to take us back to the mainland
each one of us had a broader vision than when we arrived.
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